The Pigott 2023 STAR*D Reanalysis: Why TMS Now Reaches Patients Sooner
What the 2023 Pigott reanalysis of the STAR*D trial found — a cumulative remission rate near 35% rather than the originally published 67% after four sequential antidepressant strategies — and why that revision moves TMS earlier in the treatment pathway.